BidaskClub lowered shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) from a buy rating to a hold rating in a research note published on Tuesday morning, BidAskClub reports.

A number of other research analysts have also issued reports on the company. TheStreet upgraded Amphastar Pharmaceuticals from a c rating to a b- rating in a research report on Wednesday, August 7th. Wells Fargo & Co set a $29.00 price objective on Amphastar Pharmaceuticals and gave the company a buy rating in a research report on Thursday, June 6th. Finally, Zacks Investment Research upgraded Amphastar Pharmaceuticals from a hold rating to a buy rating and set a $23.00 price objective for the company in a research report on Wednesday, July 10th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $24.64.

NASDAQ:AMPH traded down $0.07 during midday trading on Tuesday, reaching $21.55. 1,432 shares of the company traded hands, compared to its average volume of 266,062. Amphastar Pharmaceuticals has a twelve month low of $17.71 and a twelve month high of $25.43. The firm has a market capitalization of $1.04 billion, a price-to-earnings ratio of 102.95 and a beta of 1.17. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83. The company has a fifty day moving average price of $21.12 and a 200 day moving average price of $21.15.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.03 by $0.05. Amphastar Pharmaceuticals had a return on equity of 5.52% and a net margin of 16.33%. The business had revenue of $79.00 million during the quarter, compared to analyst estimates of $78.90 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. On average, equities research analysts forecast that Amphastar Pharmaceuticals will post 0.15 earnings per share for the current fiscal year.

In other Amphastar Pharmaceuticals news, CEO Jack Y. Zhang sold 300,000 shares of the business’s stock in a transaction on Wednesday, September 11th. The stock was sold at an average price of $20.82, for a total transaction of $6,246,000.00. Following the completion of the transaction, the chief executive officer now owns 2,147,316 shares in the company, valued at approximately $44,707,119.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Yakob Liawatidewi sold 5,000 shares of the business’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $20.73, for a total value of $103,650.00. Following the transaction, the senior vice president now owns 47,188 shares of the company’s stock, valued at approximately $978,207.24. The disclosure for this sale can be found here. Insiders have sold a total of 339,454 shares of company stock valued at $7,084,842 in the last 90 days. Insiders own 30.80% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the business. Comerica Bank boosted its position in Amphastar Pharmaceuticals by 2.1% during the 1st quarter. Comerica Bank now owns 34,703 shares of the company’s stock worth $730,000 after acquiring an additional 722 shares during the period. Texas Permanent School Fund raised its stake in shares of Amphastar Pharmaceuticals by 3.8% in the 1st quarter. Texas Permanent School Fund now owns 23,475 shares of the company’s stock worth $480,000 after buying an additional 851 shares in the last quarter. Prudential Financial Inc. raised its stake in shares of Amphastar Pharmaceuticals by 1.4% in the 2nd quarter. Prudential Financial Inc. now owns 63,076 shares of the company’s stock worth $1,331,000 after buying an additional 870 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Amphastar Pharmaceuticals by 15.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock worth $205,000 after buying an additional 1,314 shares in the last quarter. Finally, Swiss National Bank raised its stake in shares of Amphastar Pharmaceuticals by 2.2% in the 2nd quarter. Swiss National Bank now owns 64,400 shares of the company’s stock worth $1,359,000 after buying an additional 1,400 shares in the last quarter. Institutional investors own 47.26% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Article: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.